89bio (ETNB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

89bio Strengthens Leadership Retention With New RSUs
TipRanksDec 16 06:28 ET
Express News | 89Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ReutersNov 29 13:30 ET
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bioNov 29 00:00 ET
89bio to Participate in the 7th Annual Evercore HealthCONx Conference
89bioNov 26 00:00 ET
Insider Purchase: Chief Executive Officer of $ETNB (ETNB) Buys 10,000 Shares
Quiver QuantitativeNov 25 06:30 ET
89Bio Inc. Reports Q3 2024 Financial Results
TipRanksNov 20 22:57 ET

Comments

Jaguar8

Oct 15 07:51

NEWS

$89bio (ETNB.US)$
89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024
89bio (Nasdaq: ETNB) announced that new analyses from the Phase 2b ENLIVEN trial of pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented at the 75th Annual AASLD The Liver Meeting® 2024. The presentations include four poster sessions focusing on:
Bio...

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...

8

3

Jaguar8

May 14 07:01

$89bio (ETNB.US)$
NEWS
89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis
89bio has initiated the Phase 3 ENLIGHTEN-Cirrhosis trial for pegozafermin in patients with MASH and compensated cirrhosis (F4). This is the first FGF21 analog to reach this trial stage for this patient subset. The trial will involve 760 patients, assessing fibrosis regression at 24 months, potentially supporting ac...

Ryan fisher

Apr 2 16:06

$89bio (ETNB.US)$ 💀hope the strong buy suggestions promoter goto jail for fraud😭

Meltyy

Mar 21 01:57

According to Vantage market estimates for NASH could cross 100 Billion by 2030
NASH Basket- $Madrigal Pharmaceuticals (MDGL.US)$ $Viking Therapeutics (VKTX.US)$ $Akero Therapeutics (AKRO.US)$ $89bio (ETNB.US)$
Than we already know how big Obesity market is going to be over next decade with global 1.5 Billion obese pts
Obesity Basket $Viking Therapeutics (VKTX.US)$ $Eli Lilly and Co (LLY.US)$ $Novo-Nordisk A/S (NVO.US)$

8

2

ETNB 89bio

Trade Overview

Capital Trend

News

Comments